Refinement and revalidation of the demoralization scale

The DS-II—internal validity

Sophie Robinson, David Kissane, Joanne Brooker, Natasha Michael, Jane Fischer, Michael Franco, Courtney Hempton, Merlina Sulistio, Julie F Pallant, David M. Clarke, Susan Burney

Research output: Contribution to journalArticleResearchpeer-review

Abstract

BACKGROUND: The Demoralization Scale (DS) was initially validated in 2004 to enable the measurement of demoralization in patients with advanced cancer. Subsequent shortcomings indicated the need for psychometric strengthening. Here, the authors report on the refinement and revalidation of the DS to form the DS-II, specifically reporting the scale's internal validity. METHODS: Patients with cancer or other progressive diseases who were receiving palliative care (n = 211) completed a revised version of the 24-item DS and a measure of symptom burden (the Memorial Symptom Assessment Scale). Exploratory factor analysis and Rasch modeling were used to evaluate, modify, and revalidate the scale, providing information about dimensionality, suitability of response format, item fit, item bias, and item difficulty. Test-retest reliability was examined for 58 symptomatically stable patients at a 5-day follow-up. RESULTS: Exploratory factor analysis supported a 22-item, 2-component model. Separate Rasch modeling of each component resulted in collapsing the response option categories and removing 3 items from each component. Both final 8-item subscales met Rasch model expectations and were appropriate to sum as a 16-item total score. The DS-II demonstrated internal consistency and test-retest reliability (Meaning and Purpose subscale: α =.84; intraclass correlation [ICC] = 0.68; Distress and Coping Ability subscale: α =.82; ICC = 0.82; total DS: α =.89; ICC = 0.80). CONCLUSIONS: The DS-II is a 3-point response, self-report scale comprising 16 items and 2 subscales. Given its revalidation, psychometric strengthening, and simplification, the DS-II is an improved and more practical measure of demoralization for research and clinical use. External validation of the DS-II will be reported subsequently. Cancer 2016;122:2251–9. © 2016 American Cancer Society.

Original languageEnglish
Pages (from-to)2251-2259
Number of pages9
JournalCancer
Volume122
Issue number14
DOIs
Publication statusPublished - 15 Jul 2016

Keywords

  • adjustment
  • cancer
  • coping behavior
  • demoralization
  • psychometrics
  • Rasch modeling
  • reliability
  • validity

Cite this

Robinson, Sophie ; Kissane, David ; Brooker, Joanne ; Michael, Natasha ; Fischer, Jane ; Franco, Michael ; Hempton, Courtney ; Sulistio, Merlina ; Pallant, Julie F ; Clarke, David M. ; Burney, Susan. / Refinement and revalidation of the demoralization scale : The DS-II—internal validity. In: Cancer. 2016 ; Vol. 122, No. 14. pp. 2251-2259.
@article{af6628b449ea4d3bbe5a6446d0e76b06,
title = "Refinement and revalidation of the demoralization scale: The DS-II—internal validity",
abstract = "BACKGROUND: The Demoralization Scale (DS) was initially validated in 2004 to enable the measurement of demoralization in patients with advanced cancer. Subsequent shortcomings indicated the need for psychometric strengthening. Here, the authors report on the refinement and revalidation of the DS to form the DS-II, specifically reporting the scale's internal validity. METHODS: Patients with cancer or other progressive diseases who were receiving palliative care (n = 211) completed a revised version of the 24-item DS and a measure of symptom burden (the Memorial Symptom Assessment Scale). Exploratory factor analysis and Rasch modeling were used to evaluate, modify, and revalidate the scale, providing information about dimensionality, suitability of response format, item fit, item bias, and item difficulty. Test-retest reliability was examined for 58 symptomatically stable patients at a 5-day follow-up. RESULTS: Exploratory factor analysis supported a 22-item, 2-component model. Separate Rasch modeling of each component resulted in collapsing the response option categories and removing 3 items from each component. Both final 8-item subscales met Rasch model expectations and were appropriate to sum as a 16-item total score. The DS-II demonstrated internal consistency and test-retest reliability (Meaning and Purpose subscale: α =.84; intraclass correlation [ICC] = 0.68; Distress and Coping Ability subscale: α =.82; ICC = 0.82; total DS: α =.89; ICC = 0.80). CONCLUSIONS: The DS-II is a 3-point response, self-report scale comprising 16 items and 2 subscales. Given its revalidation, psychometric strengthening, and simplification, the DS-II is an improved and more practical measure of demoralization for research and clinical use. External validation of the DS-II will be reported subsequently. Cancer 2016;122:2251–9. {\circledC} 2016 American Cancer Society.",
keywords = "adjustment, cancer, coping behavior, demoralization, psychometrics, Rasch modeling, reliability, validity",
author = "Sophie Robinson and David Kissane and Joanne Brooker and Natasha Michael and Jane Fischer and Michael Franco and Courtney Hempton and Merlina Sulistio and Pallant, {Julie F} and Clarke, {David M.} and Susan Burney",
year = "2016",
month = "7",
day = "15",
doi = "10.1002/cncr.30015",
language = "English",
volume = "122",
pages = "2251--2259",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley & Sons",
number = "14",

}

Refinement and revalidation of the demoralization scale : The DS-II—internal validity. / Robinson, Sophie; Kissane, David; Brooker, Joanne; Michael, Natasha; Fischer, Jane; Franco, Michael; Hempton, Courtney; Sulistio, Merlina; Pallant, Julie F; Clarke, David M.; Burney, Susan.

In: Cancer, Vol. 122, No. 14, 15.07.2016, p. 2251-2259.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Refinement and revalidation of the demoralization scale

T2 - The DS-II—internal validity

AU - Robinson, Sophie

AU - Kissane, David

AU - Brooker, Joanne

AU - Michael, Natasha

AU - Fischer, Jane

AU - Franco, Michael

AU - Hempton, Courtney

AU - Sulistio, Merlina

AU - Pallant, Julie F

AU - Clarke, David M.

AU - Burney, Susan

PY - 2016/7/15

Y1 - 2016/7/15

N2 - BACKGROUND: The Demoralization Scale (DS) was initially validated in 2004 to enable the measurement of demoralization in patients with advanced cancer. Subsequent shortcomings indicated the need for psychometric strengthening. Here, the authors report on the refinement and revalidation of the DS to form the DS-II, specifically reporting the scale's internal validity. METHODS: Patients with cancer or other progressive diseases who were receiving palliative care (n = 211) completed a revised version of the 24-item DS and a measure of symptom burden (the Memorial Symptom Assessment Scale). Exploratory factor analysis and Rasch modeling were used to evaluate, modify, and revalidate the scale, providing information about dimensionality, suitability of response format, item fit, item bias, and item difficulty. Test-retest reliability was examined for 58 symptomatically stable patients at a 5-day follow-up. RESULTS: Exploratory factor analysis supported a 22-item, 2-component model. Separate Rasch modeling of each component resulted in collapsing the response option categories and removing 3 items from each component. Both final 8-item subscales met Rasch model expectations and were appropriate to sum as a 16-item total score. The DS-II demonstrated internal consistency and test-retest reliability (Meaning and Purpose subscale: α =.84; intraclass correlation [ICC] = 0.68; Distress and Coping Ability subscale: α =.82; ICC = 0.82; total DS: α =.89; ICC = 0.80). CONCLUSIONS: The DS-II is a 3-point response, self-report scale comprising 16 items and 2 subscales. Given its revalidation, psychometric strengthening, and simplification, the DS-II is an improved and more practical measure of demoralization for research and clinical use. External validation of the DS-II will be reported subsequently. Cancer 2016;122:2251–9. © 2016 American Cancer Society.

AB - BACKGROUND: The Demoralization Scale (DS) was initially validated in 2004 to enable the measurement of demoralization in patients with advanced cancer. Subsequent shortcomings indicated the need for psychometric strengthening. Here, the authors report on the refinement and revalidation of the DS to form the DS-II, specifically reporting the scale's internal validity. METHODS: Patients with cancer or other progressive diseases who were receiving palliative care (n = 211) completed a revised version of the 24-item DS and a measure of symptom burden (the Memorial Symptom Assessment Scale). Exploratory factor analysis and Rasch modeling were used to evaluate, modify, and revalidate the scale, providing information about dimensionality, suitability of response format, item fit, item bias, and item difficulty. Test-retest reliability was examined for 58 symptomatically stable patients at a 5-day follow-up. RESULTS: Exploratory factor analysis supported a 22-item, 2-component model. Separate Rasch modeling of each component resulted in collapsing the response option categories and removing 3 items from each component. Both final 8-item subscales met Rasch model expectations and were appropriate to sum as a 16-item total score. The DS-II demonstrated internal consistency and test-retest reliability (Meaning and Purpose subscale: α =.84; intraclass correlation [ICC] = 0.68; Distress and Coping Ability subscale: α =.82; ICC = 0.82; total DS: α =.89; ICC = 0.80). CONCLUSIONS: The DS-II is a 3-point response, self-report scale comprising 16 items and 2 subscales. Given its revalidation, psychometric strengthening, and simplification, the DS-II is an improved and more practical measure of demoralization for research and clinical use. External validation of the DS-II will be reported subsequently. Cancer 2016;122:2251–9. © 2016 American Cancer Society.

KW - adjustment

KW - cancer

KW - coping behavior

KW - demoralization

KW - psychometrics

KW - Rasch modeling

KW - reliability

KW - validity

UR - http://www.scopus.com/inward/record.url?scp=85027923275&partnerID=8YFLogxK

U2 - 10.1002/cncr.30015

DO - 10.1002/cncr.30015

M3 - Article

VL - 122

SP - 2251

EP - 2259

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 14

ER -